Childhood Cancer Clinical Trial
— ZERO2Official title:
Precision Medicine for Every Child With Cancer
NCT number | NCT05504772 |
Other study ID # | ZERO2 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | December 16, 2022 |
Est. completion date | July 2030 |
To improve outcomes for childhood cancer patients through the implementation of precision medicine.
Status | Recruiting |
Enrollment | 3500 |
Est. completion date | July 2030 |
Est. primary completion date | July 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 0 Years to 25 Years |
Eligibility | Inclusion Criteria: 1. Age < 18 years Note: Individual patients aged 19 - 25 years old with a pediatric cancer, e.g., neuroblastoma, may be enrolled after discussion with, and at the discretion of, the Study Chair or their delegate. 2. Life expectancy >6 weeks at time of enrolment 3. Consent i. Signed and dated informed consent for study enrolment from participant aged = 18 years or from parent/guardian of participant aged <18 years. ii. Separate signed and dated informed consent for understanding the role of germline testing and choice for the return of germline results. |
Country | Name | City | State |
---|---|---|---|
Australia | Women's and Children's Hospital | Adelaide | |
Australia | Queensland Children's Hospital | Brisbane | |
Australia | Royal Hobart Hospital | Hobart | |
Australia | Monash Children's Hospital | Melbourne | |
Australia | Royal Children's Hospital | Melbourne | |
Australia | John Hunter Children's Hospital | Newcastle | |
Australia | Perth Children's Hospital | Perth | |
Australia | Sydney Children's Hospital, Randwick | Sydney | |
Australia | The Children's Hospital at Westmead | Sydney |
Lead Sponsor | Collaborator |
---|---|
Australian & New Zealand Children's Haematology/Oncology Group | Children's Cancer Institute (CCI), Medical Research Future Fund, Minderoo Foundation |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Utility of recommended personalized therapy for HR childhood cancer patients. | Disease control rate (stable disease + partial response + complete response) in HR patients who have received recommended personalized therapy which are molecularly and/or preclinically directed | 5 years | |
Primary | Utility of recommended personalized therapy for non-HR childhood cancer patients. | The proportion of non-HR patients for whom the disease specific, clinically relevant, virtual molecular panel provides additional or equivalent results for diagnosis and risk stratification when compared with routine diagnostic tests. | 5 years | |
Secondary | Utility of pre-defined virtual molecular panel for non-HR childhood cancer patients. | The proportion of non-HR patients for whom a pre-defined virtual molecular panel; leads to a streamline molecular report issued within 4 weeks from receipt of samples, changes or refines the initial histopathological diagnosis, changes or refines risk stratification at diagnosis, changes or refines treatment at diagnosis and/or facilitates enrolment in clinical trials requiring prior molecular studies. | 5 years | |
Secondary | Utility of comprehensive precision medicine for patients with rare tumors in childhood. | Proportion of rare cancer cohort patients for which comprehensive precision medicine improves diagnosis, identifies at least one therapeutic target or facilitates improvement in therapy within a clinically relevant timeframe. | 5 years | |
Secondary | Utility of Molecular Tumour Board (MTB) recommendation tier system for HR childhood cancer patients. | Evaluation of the correlation of MTB recommendation tier to treatment outcome, clinician rated value of MTB recommendation tier in facilitating therapeutic decision and drug access and proportion of HR patients for which the MTB recommendation improves diagnosis, risk stratification or facilitates improvement in therapy within a clinically relevant timeframe. | 5 years | |
Secondary | Utility of preclinical testing in HR childhood cancer patients. | Evaluation of proportion of tumors where in vitro sensitivity testing can be successfully performed compared with PRISM trial, turnaround time for preclinical in vitro and in vivo drug testing, proportion of tumors where in vitro drug sensitivity identifies additional molecular drivers and proportion of patients for whom preclinical testing:
i. Facilitates therapeutic decision ii. Identifies additional therapeutic options in patients for whom genomic profiling did not identify molecular targets iii. Predicts clinical outcome |
5 years | |
Secondary | Clinical utility of germline WGS in patients with childhood cancers. | Evaluation of;
Proportion of HR and non-HR patients with a reportable germline finding (i. For whom the result was not previously known ii. For whom the results would have been missed using current clinical testing criteria) Proportion of patients for whom medical management for the current cancer and future cancer risk has been altered based on the germline findings |
5 years | |
Secondary | Treatment outcome in HR childhood cancer patients who have received recommended personalised therapy which are molecularly and/or preclinically directed. | Evaluation of;
Objective response in patients who have received single agent versus combination personalized therapy Disease control (stable disease + partial response + complete response) in patients who have received a single agent versus combination personalized therapy Progression-free interval (PFI) ratio: PFI personalized therapy : PFI conventional therapy Difference in outcome between patients have received recommended personalised therapy and those who did not (i. Proportion of patients without progression or death at 6 and 12 months between the two groups ii. Difference in progression-free and overall survival between the two groups) |
5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04202094 -
Fertility in Young Adults Who Did (Not) Store Testicular Tissue Before a Treatment Leading to Fertility Problems
|
N/A | |
Active, not recruiting |
NCT03336931 -
PRecISion Medicine for Children With Cancer
|
||
Not yet recruiting |
NCT05048771 -
Fertility and Temporality in Pediatric Oncology
|
||
Completed |
NCT05982379 -
Motivation Program for Children With Cancer
|
N/A | |
Completed |
NCT04066218 -
Sexual Function Screening in Childhood Cancer Survivors
|
||
Completed |
NCT03934060 -
Strength Training and ADLs in Childhood Leukemia and Lymphoma Patients
|
N/A | |
Active, not recruiting |
NCT03938324 -
Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions
|
N/A | |
Active, not recruiting |
NCT04032743 -
Risk Factors and Treatment Outcome of Oncology Children Hospitalized in the Intensive Care Unit Due to Sepsis
|
||
Active, not recruiting |
NCT04328350 -
Social Experiences of Adolescents and Young Adults With Cancer
|
||
Not yet recruiting |
NCT05457153 -
Technology-Based Well-Being Process Program (WEBEPROP) for Children and Adolescents in Palliative Care
|
N/A | |
Recruiting |
NCT05641961 -
Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care
|
N/A | |
Completed |
NCT06179914 -
Resilience Models in Adolescence and Youth With Cancer in Taiwan
|
||
Completed |
NCT03951246 -
Cognitive and Motor Training in Pediatric Posterior Fossa Tumor Survivors
|
N/A | |
Not yet recruiting |
NCT04902313 -
Cultivating Resilience in Oncology Practice
|
N/A | |
Completed |
NCT03160768 -
Feasibility of Isolating P16 Expression
|
||
Recruiting |
NCT06053268 -
Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors
|
N/A | |
Recruiting |
NCT06411704 -
Remote Exercise Video Adaptations to Maximize Physical Activity in Childhood Cancer
|
||
Withdrawn |
NCT02130934 -
Cardiac 3D MRI in Pediatric Cancer Patients
|
N/A | |
Completed |
NCT02216604 -
Exercise in Pediatric Cancer Patient Undergoing Anti-Cancer Treatment
|
N/A | |
Recruiting |
NCT03852758 -
Green Exercise for Cancer - Creating Opportunities for Survivors
|
N/A |